Form 8.3 - Dechra Pharmaceuticals pl | Company Announcement

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

(a) Full name of discloser:	SOCIETE GENERALE SA
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor, and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	Dechra Pharmaceuticals plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure	09/01/2024
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"	NO

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	6,160,010	5.41	47,482	0.04
(2) Cash-settled derivatives:	0	0.00	4,625,880	4.06
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	0	0.00	0	0.00
TOTAL:	6,160,010	5.41	4,673,362	4.10

Class of relevant security	Purchase/sale	Number of securities	Price per unit GBP
1p ordinary	Purchase	404	38.6
1p ordinary	Purchase	440	38.6
1p ordinary	Purchase	36	38.6
1p ordinary	Purchase	440	38.6
1p ordinary	Purchase	440	38.6
1p ordinary	Purchase	8,805	38.62
1p ordinary	Purchase	220	38.6
1p ordinary	Purchase	44	38.62
1p ordinary	Purchase	440	38.6
1p ordinary	Purchase	1,587	38.62
1p ordinary	Purchase	297	38.6
1p ordinary	Sale	12	38.6
1p ordinary	Sale	68	38.6
1p ordinary	Sale	71	38.6
1p ordinary	Sale	118	38.6
1p ordinary	Sale	200	38.6
1p ordinary	Sale	300	38.6
1p ordinary	Sale	510	38.6
1p ordinary	Sale	601	38.6
1p ordinary	Sale	700	38.6
1p ordinary	Sale	112	38.6
1p ordinary	Sale	355	38.6
1p ordinary	Sale	510	38.6
1p ordinary	Sale	36	38.6
1p ordinary	Sale	51	38.6
1p ordinary	Sale	90	38.6
1p ordinary	Sale	195	38.6
1p ordinary	Sale	203	38.6
1p ordinary	Sale	220	38.6
1p ordinary	Sale	238	38.6
1p ordinary	Sale	293	38.6
1p ordinary	Sale	297	38.6
1p ordinary	Sale	428	38.6
1p ordinary	Sale	440	38.6
1p ordinary	Sale	440	38.6
1p ordinary	Sale	440	38.6
1p ordinary	Sale	440	38.6
1p ordinary	Sale	466	38.6
1p ordinary	Sale	483	38.6
1p ordinary	Sale	495	38.6
1p ordinary	Sale	517	38.6
1p ordinary	Sale	537	38.6
1p ordinary	Sale	709	38.6
1p ordinary	Sale	747	38.6
1p ordinary	Sale	849	38.6

Date of disclosure:	10/01/2024
Contact name:	Paul Jenkins
Telephone number:	+44 20 7676 6969

Form 8.3 - Dechra Pharmaceuticals pl

Date of disclosure:

Contact name:

Telephone number:

Companies

UK 100

Latest directors dealings

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages: